{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:56:44Z","timestamp":1768895804640,"version":"3.49.0"},"reference-count":28,"publisher":"Impact Journals, LLC","issue":"65","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,12,12]]},"DOI":"10.18632\/oncotarget.22499","type":"journal-article","created":{"date-parts":[[2017,11,18]],"date-time":"2017-11-18T14:35:46Z","timestamp":1511015746000},"page":"108480-108491","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults"],"prefix":"10.18632","volume":"8","author":[{"given":"Xinghua","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Chinese PLA General Hospital, Beijing, China"},{"name":"Department of Dermatology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"He","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,11,18]]},"reference":[{"key":"1","first-page":"338","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Krol","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Novak","year":"2016","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Mastey","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-2133.2003.05092.x","article-title":"Prevalence of atopic dermatitis in Japanese adults","volume":"148","author":"Ogawa","year":"2003","journal-title":"Br J Dermatol"},{"key":"5","first-page":"116","article-title":"Guidelines of care for the management of atopic dermatitis. Section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Feldman","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"6","first-page":"327","article-title":"Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Paller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Schmitt","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"8","first-page":"35","article-title":"Targeting key proximal drivers in type 2 inflammation in disease","volume":"15","author":"Yancopoulos","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Guttman-Yassky","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt.15.69","article-title":"Drug evaluation review: dupilumab in atopic dermatitis","volume":"7","author":"Guttman-Yassky","year":"2015","journal-title":"Immunotherapy"},{"key":"11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: First Global Approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Pirozzi","year":"2014","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Weinstein","year":"2016","journal-title":"Lancet"},{"key":"14","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Poulin","year":"2016","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Griffiths","year":"2017","journal-title":"Lancet"},{"key":"16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/bjd.13662","article-title":"What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study","volume":"172","author":"Simpson","year":"2015","journal-title":"Br J Dermatol"},{"key":"17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards","volume":"74","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"18","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1111\/j.1468-3083.2012.04578.x","article-title":"Relationship between itch and psychological status of patients with atopic dermatitis","volume":"27","author":"Szepietowski","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"19","first-page":"44","article-title":"Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study","volume":"104","author":"Surinyac","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1521\/suli.2006.36.1.120","article-title":"Prevalence of suicidal ideation in patients with atopic dermatitis","volume":"36","author":"Kimata","year":"2006","journal-title":"Suicide Life Threat Behav"},{"key":"21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","article-title":"Mental health comorbidity in patients with atopic dermatitis","volume":"131","author":"Simpson","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"22","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjd.12590","article-title":"Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods","volume":"169","author":"Williams","year":"2013","journal-title":"Br J Dermatol"},{"key":"23","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1007\/s11136-014-0719-3","article-title":"A comparison of three methods of assessing differential item functioning (DIF) in the Hospital Anxiety Depression Scale: ordinal logistic regression, Rasch analysis and the Mantel chi-square procedure","volume":"23","author":"Reid","year":"2014","journal-title":"Qual Life Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Mastey","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"25","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials","volume":"137","author":"Maurer","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"26","first-page":"1","article-title":"Atopic dermatitis 2017: where we were 10-15 years ago in psoriasis","volume":"30","author":"Wu","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"27","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","article-title":"Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials","volume":"140","author":"Yao","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"28","first-page":"d5928","article-title":"Cochrane Bias Methods Group. Cochrane Statistical Methods Group","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T15:17:19Z","timestamp":1589210239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,18]]},"references-count":28,"journal-issue":{"issue":"65","published-print":{"date-parts":[[2017,12,12]]}},"alternative-id":["22499","29312544"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.22499","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,18]]}}}